Monoclonal antibodies are the fastest growing segment within the biotech and pharmaceutical industry. Today, four of the top ten selling blockbusters are antibodies. Industry forecasts see global antibody sales rising to $58bn in 2014. Pharma and biotech companies are investing heavily in developing new antibodies to treat a rising number of diseases.

However, antibody concepts also have their limitations. Reimbursement is becoming increasingly difficult in the light of a high price and cost savings in global health delivery, with forthcoming biosimilars applying pressure on the pricing of antibody therapies. Antibody targets are also limited to the surface of the cell and a growing number of alternative active and passive immune therapies will deliver fresh therapeutic concepts to the doctor’s menu.

This BIOCOM Event offers a unique opportunity to gain insight into the strategies of pharma and biotech companies. Leading experts in the field of immune therapies will share their knowledge on how to successfully develop and market new concepts.

Find a picture gallery and a video on the |transkript website (in German).

Programme

09:30

Welcome Address

Marnix Krop,
Ambassador of the Kingdom of the Netherlands

 

 

Introduction

Innovation Support in the Netherlands

Guido Landheer,
Director Top Sectors and Industrial Policy Department,
Ministry of Economic Affairs, NL



 

Keynote

Fulfilling the Promises of Personalised Healthcare?

Prof. Dr. Jochen Maas,
Managing Director,
Sanofi Deutschland GmbH



 

Market Overview

Capital Markets View on Personalised Healthcare

Sachin Soni,
Director Research, Kempen & Co, NL



10:50

Coffee Break

11:30

Patents

A Brief History of Diagnostics Patents

Dr. Hans-Rainer Jaenichen,
Partner, Vossius & Partner



 

Patents

Patenting Biomarkers and DNA – the US practice

Dr. Jennifer Gordon
Partner, BakerBotts, US



 

Patents

Patenting Biomarkers and DNA – the US practice

Dr. Aliki Nichogiannopoulou
Director Biotechnology, European Patent Office



12:30

Lunch

13:30

Development

Challenges in Co-developing a Drug and a Companion Diagnostics

Dr. Gabriele Pestlin,
Diagnostics Liaison Manager Oncology,
Roche Diagnostics GmbH



 

Academia

Diagnostics and DNA – Solutions for Managing Large Amounts of Data

Prof. Dr. Peter van der Spek,
Head of IT Department, Erasmus University Rotterdam, NL



 

Biotech

Genetic Profiling for better Treatments

Dr. Iris Simon,
Senior Director Research & Development,
Agendia NV, NL



 

Diagnostics

Diagnostics – the Customer's Needs

Dr. Jos Rijntjes,
Head Commercial Operations, Handheld Diagnostics, Philips Healthcare Incubator, NL



14:50

Coffee Break

15:20

Public Affairs

Evaluation for Reimbursement of Diagnostics

Mirella Marlow, Programme Director,
Devices & Diagnostic Systems, NICE Institute, UK



 

Regulatory

European Framework

Dr. Tobias Ostler,
regulanet®



 

Regulatory

European Framework

Dr. Heiner Lüdemann,
TÜV Rheinland LGA Products GmbH



 

Strategy

Market Access for Next Generation Diagnostics

Prof. Dr. Stephen Little, Vice President, Personalized Healthcare, Qiagen NV



 

Perspectives

New Solutions for the Future of Health

Mathis Brauchbar
CEO, evalueSCIENCE, CH



 

16:40

Discussion/Wrap-up

Dr. Claire Skentelbery,
Secretary General European Biotechnology Network



17:00

Cocktail Reception & Guided Embassy Tour

When & where

CONTACT & INFORMATION

 

 

Uta Holmer

Dipl.-Volkswirtin

Veranstaltungsmanagement

 

 

Telefon: +49-30-264921-53

events[at]biocom.de